In conclusion, our findings demonstrate that IR-associated diabetes promotes the development and progression of PD through PLK2-mediated mitochondrial dysfunction, upregulated ROS production, and enhanced SNCA signaling; thus, suggesting the therapeutic targetability of PLK2 and/or SNCA as potentially novel disease-modifying strategies in patients with PD. This evidence concerns the gene SNCA and Parkinson disease.